Characterization of osteolytic, osteoblastic, and mixed lesions in a prostate cancer mouse model using 18F-FDG and 18F-fluoride PET/CT
about
The reaction of bone to tumor growth from human breast cancer cells in a rat spine single metastasis model.A novel patient-derived intra-femoral xenograft model of bone metastatic prostate cancer that recapitulates mixed osteolytic and osteoblastic lesions.Combined inhibition of the BMP pathway and the RANK-RANKL axis in a mixed lytic/blastic prostate cancer lesionDifferential expression of the RANKL/RANK/OPG system is associated with bone metastasis in human non-small cell lung cancer.Applications of immunoPET: using 124I-anti-PSCA A11 minibody for imaging disease progression and response to therapy in mouse xenograft models of prostate cancer.Molecular mechanisms of bone 18F-NaF deposition.Androgen-independent molecular imaging vectors to detect castration-resistant and metastatic prostate cancer.The IGR-CaP1 xenograft model recapitulates mixed osteolytic/blastic bone lesions observed in metastatic prostate cancerFunctional imaging for prostate cancer: therapeutic implications.Molecular imaging of prostate cancer: PET radiotracers.Comparisons between glucose analogue 2-deoxy-2-((18)F)fluoro-D-glucose and (18)F-sodium fluoride positron emission tomography/computed tomography in breast cancer patients with bone lesionsCD90 (Thy-1)-positive selection enhances osteogenic capacity of human adipose-derived stromal cellsQuantification of skeletal blood flow and fluoride metabolism in rats using PET in a pre-clinical stress fracture model.An abundant perivascular source of stem cells for bone tissue engineering.Influence of simultaneous targeting of the bone morphogenetic protein pathway and RANK/RANKL axis in osteolytic prostate cancer lesion in bone.Prostate cancer metastases alter bone mineral and matrix composition independent of effects on bone architecture in mice--a quantitative study using microCT and Raman spectroscopy.Animal tumor models for PET in drug development.Baseline increased 18F-fluoride uptake lesions at vertebral corners on positron emission tomography predict new syndesmophyte development in ankylosing spondylitis: a 2-year longitudinal study.Human Cell Surface Receptors as Molecular Imaging Candidates for Metastatic Prostate Cancer.Targeting the alphavbeta3 integrin for small-animal PET/CT of osteolytic bone metastasesImaging technologies for preclinical models of bone and joint disorders.Comparison of NaF and FDG PET/CT for assessment of treatment response in castration-resistant prostate cancers with osseous metastases.18 F-Fluoride positron emission tomography/computed tomography for noninvasive in vivo quantification of pathophysiological bone metabolism in experimental murine arthritis.Optimizing an 18F-NaF and 18F-FDG cocktail for PET assessment of metastatic castration-resistant prostate cancer.In Molecular Pursuit of Bone Metastasis by Fluciclovine PET.PCSD1, a new patient-derived model of bone metastatic prostate cancer, is castrate-resistant in the bone-niche.Insights into bone metabolism of avian embryos in ovo via 3D and 4D 18F-fluoride positron emission tomography.An in vivo mouse model of intraosseous spinal cancer causing evolving paraplegia.Utility of F-18 FDG PET/CT for Detection of Bone Marrow Metastases in Prostate Cancer Patients Treated with Radium-223.Evaluation of osteogenic cell differentiation in response to bone morphogenetic protein or demineralized bone matrix in a critical sized defect model using GFP reporter mice.Specific bone region localization of osteolytic versus osteoblastic lesions in a patient-derived xenograft model of bone metastatic prostate cancer.Critical considerations on the combined use of ¹⁸F-FDG and ¹⁸F-fluoride for PET assessment of metastatic bone disease.Deletion of Orai1 leads to bone loss aggravated with aging and impairs function of osteoblast lineage cells.
P2860
Q30415248-4C51B651-E8CE-4B10-9C21-DF1EE19F46FBQ30504566-8DA10798-92B1-4BCF-89F7-FD4328A38F52Q34574593-133E3450-CE70-4FE2-AA11-6944A3774BF2Q34629549-39D40587-7B45-4949-933F-B591C6898E92Q34717742-FBDEF4BB-42A4-43FF-A24B-A542A9314C3CQ35203602-5E45CE89-61CE-481C-996B-1EF2E5AF9EACQ35256725-32436196-DB8A-462A-B4F2-9F2EF73147C7Q36062138-86703FAC-04A9-4EA5-A281-560061AE3D85Q36128629-0C109AEF-382D-4FCE-A5A8-B1F5E145A9DCQ36129937-7C5868DB-064D-44C6-A8E9-308CC3BEBA18Q36627805-3DA195D0-A67E-4930-8D52-40C072B826DFQ36661179-308471DF-E47E-4B0B-BD29-0783B861E447Q36672286-69753499-4C8E-4845-B966-92733CE0FE06Q36861687-1A02BE2C-22CF-4F92-8921-A399A2F4302BQ37131738-C22EE74B-B0A6-43CF-A7BD-79110DDAB141Q37237676-F3DEA9D0-418A-4FBD-AAA7-0C43381528E3Q37924161-909D16E4-B572-4996-AD82-3003B2BD7E64Q38762450-B508FEBD-A625-4A00-B210-F584D3C46894Q39017903-87D92659-F73B-47EC-80CD-0D77438ADF5EQ39565634-8EC51D52-4C6F-42CA-B8D8-4DAE31306006Q40157649-C02FA767-8ADB-4DBA-AB6E-AE5BF74AD24EQ40215364-75D5E6BD-BF62-460E-82B7-7162E71B5A6EQ41811951-0BD1325D-2CDC-4440-B6B4-57257805F726Q42095619-F560DDF5-1D30-4AB6-921F-A6EA35C207DCQ42335925-F74CA039-7A47-4D2D-B6E7-2D1EBCCB7FF9Q42938836-5E318FDB-E029-4F02-9E00-FDEF5009BFCDQ44359350-6412F821-0C30-4EAF-9C59-C71D2488B95DQ46082350-D0869CE6-B510-4535-9F22-36A5D3A0BFD5Q49363173-C09A8A66-C1CB-4935-92F0-D01315EC9530Q50455412-79E2B39C-B840-4BF2-9FE7-B2BFC2521DF1Q52900925-DA7E1B6A-824E-44E2-B3F3-5E5736082248Q53108614-32F7DB2E-5BEB-4363-A486-480131E88025Q55362597-B3DEB6DD-E954-4B87-B1E6-A98764F8C37E
P2860
Characterization of osteolytic, osteoblastic, and mixed lesions in a prostate cancer mouse model using 18F-FDG and 18F-fluoride PET/CT
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Characterization of osteolytic ...... 8F-FDG and 18F-fluoride PET/CT
@en
type
label
Characterization of osteolytic ...... 8F-FDG and 18F-fluoride PET/CT
@en
prefLabel
Characterization of osteolytic ...... 8F-FDG and 18F-fluoride PET/CT
@en
P2093
P2860
P1476
Characterization of osteolytic ...... 8F-FDG and 18F-fluoride PET/CT
@en
P2093
Arion F Chatziioannou
Brian T Feeley
David B Stout
Jay R Lieberman
Mandeep S Virk
Wellington K Hsu
P2860
P304
P356
10.2967/JNUMED.107.045666
P407
P577
2008-02-20T00:00:00Z